BioMarin's Much-Anticipated GALNS Trial Starts in MPS IVA
By Jennifer Boggs
Wednesday, February 2, 2011
BioMarin Pharmaceutical Inc. launched a pivotal Phase III trial of enzyme replacement therapy (ERT) GALNS (N-acetylgalactosamine 6-sulfatase), the drug widely considered to be a key growth driver for the Novato, Calif.-based biotech.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.